Minerva Neurosciences, Inc. Proceeds from Sale and Maturity of Marketable Securities
Minerva Neurosciences, Inc. (NERV) reported Proceeds from Sale and Maturity of Marketable Securities of $5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-07
- Minerva Neurosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2018-09-30 was $29.50M.
- Minerva Neurosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2018-06-30 was $36.10M.
- Minerva Neurosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2018-03-31 was $39.25M.
- Minerva Neurosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2017-12-31 was $0.00.
- Minerva Neurosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2017 was $27.39M, a 53.72% increase from fiscal 2016.
- Minerva Neurosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2016 was $17.82M, a 256.74% increase from fiscal 2015.
- Minerva Neurosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2015 was $4.99M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.00M 10-Q · filed 2026-08-07 | |||
| 2018-09-30 | $29.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $65.60M derived: sum of 2 quarters · filed 2018-11-05 | $104.85M 10-Q · filed 2018-11-05 | $104.85M derived: sum of 4 quarters · filed 2018-11-05 |
| 2018-06-30 | $36.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $75.35M 10-Q · filed 2018-08-02 | $75.35M derived: sum of 3 quarters · filed 2018-08-02 | |
| 2018-03-31 | $39.25M 10-Q · filed 2018-05-03 | $39.25M derived: sum of 2 quarters · filed 2018-05-03 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $27.39M 10-K · filed 2018-03-12 | ||
| 2017-09-30 | $27.39M 10-Q · filed 2018-11-05 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $8.38M derived: sum of 2 quarters · filed 2018-03-12 | $9.78M derived: sum of 3 quarters · filed 2018-03-12 | $17.82M 10-K · filed 2018-03-12 |
| 2016-09-30 | $8.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $9.78M derived: sum of 2 quarters · filed 2017-11-06 | $17.82M 10-Q · filed 2017-11-06 | $21.87M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $9.44M 10-Q · filed 2017-08-03 | $13.49M derived: sum of 3 quarters · filed 2018-03-12 | |
| 2016-03-31 | $8.04M 10-Q · filed 2017-05-04 | $12.09M derived: sum of 2 quarters · filed 2018-03-12 | ||
| 2015-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $4.99M 10-K · filed 2018-03-12 | ||
| 2015-09-30 | $944.68K 10-Q · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |